Pharmacy Drug Policy & Procedure

Policy Name:	Statin (HMG CoA reductase inhibitor), Brand Name	Policy #:	1905P

Purpose of the Policy

The purpose of this policy is to establish the criteria for the coverage of branded HMG CoA reductase inhibitors.

Statement of the Policy

Branded statin medications such as Altoprev (lovastatin extended-release), Ezallor Sprinkle (rosuvastatin), Livalo (pitavastatin), Lescol XL (fluvastatin), and Zypitamag (pitavastatin magnesium) may be covered if the following criteria for coverage have been met.

Criteria

1. Criteria for Coverage of a Brand-Name Statin

1.1 A confirmed diagnosis of hyperlipidemia, with recent LDL level submitted to support diagnosis

1.2 Documented failure to achieve cholesterol goals with one of the following:

- Maximum tolerated high intensity dose of atorvastatin (40mg or 80mg) or rosuvastatin (20mg or 40mg) after at least 90 days of therapy
- Documented intolerance with any two of the following statins:
  - Atorvastatin
  - Lovastatin
  - Pravastatin
  - Rosuvastatin
  - Simvastatin

2. Criteria for Coverage of Ezallor Sprinkle

2.1 Age 7 years or older

2.2 Documentation that the member is unable to swallow rosuvastatin tablets due to an underlying medical condition or documentation that the drug is being administered via a gastric tube

3. Approval Period

3.1 Initial: 12 months

3.2 Reauthorization: 12 months with documented clinical benefit

CPT Codes

HCPCS Codes

References

1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

J Am Coll Cardiol. 2019 Jun 25;73(24):e285- e350.
2. American College of Cardiology Solution Set Oversight Committee 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418.

Created Date: 06/06/12
Effective Date: 01/01/13
Posted to Website: 01/01/22
Revision Date: 06/05/24